ESOC 2021 | Hemorrhagic stroke: what’s on the horizon?
Heinrich Audebert, MD, Charité, Center for Stroke Research Berlin, Berlin, Germany, shares his insight into future treatments for hemorrhagic stroke, a condition where prognosis is poor and there is a lack of effective evidence-based treatments. Prof. Audebert is hopeful that the coming years will see the development of effective treatments for hemorrhagic stroke, as well as a critical shift towards pre-hospital care. Studies have shown the dispatch of mobile stroke units (MSUs) immediately after the onset of stroke symptoms to be beneficial. Thus, treatments may move to a prehospital setting to ensure patients receive proper treatment on time. Investigations into neuroprotection and neurorehabilitation are also growing fields. The major challenge will be applying these novel approaches to the right patients. This interview took place at the European Stroke Organisation Conference (ESOC), 2021.
Disclosures
Prof. Audebert reports the following disclosures:
I am the Principle Investigator of the INSPIRE-TMS and the B_PROUD studies, as well as the ULTRAFAST prehospital stroke diagnostics project. I have been member of the Flying Interventionalist Team study steering committee.
I have received honoraria for speaker and consultancy activities from Novo-Nordisk, Pfizer, MBS, Boehringer Ingelheim, Bayer Healthcare, and Medpoint. I have received institutional funding for the different areas of my research from the German Federal Ministry for Education and Research, the Deutsche Forschung Gemeinschaft, the German Innovation-Funds and the Stiftung Deutsche Schlaganfall-Hilfe.
